News
Laurent Pharmaceuticals Starts Phase 3 Study with Once-a-Day Oral COVID-19 Antiviral Treatment Candidate in Hospitalized Moderate-to-Severe Patients
15 February 2022
Following the positive outcome of a meeting with the FDA, a first patient was recruited in the Phase 3 expansion of...
Read MoreLaurent Pharmaceuticals extends COVID-19 Phase 2 study with oral antiviral LAU-7b that has showed 100% reduction in the risk of progression onto mechanical ventilation and death
15 December 2021
FDA allows Phase 2 study extension focusing on moderate-to-severe COVID-19 patients and grants Type B meeting to discuss eligibility to Emergency...
Read MoreEVENTS
Laurent Pharma to participate to BIO International Convention, June 13-16, 2022 – San Diego, CA
Laurent Pharma to participate to BIO-Europe Spring, March 28-31, 2022
Laurent Pharma to participate to BiotechGate, February 7-9, 2022
Laurent Pharma to participate to Biotech Showcase, January 9-11 and 17-19, 2022
Laurent Pharma to participate to H.C. Wainwright 23rd Annual Global Investment Conference,
September 13-15, 2021
September 13-15, 2021